Clinical trial
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
NCT00019630 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019630 |
|---|---|
| Title | Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors |
| Official title | Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor, Kidney Tumor |
| Intervention type | Drug |
| Interventions | doxorubicin HCl liposome |
| Start date | Jul 1, 1999 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: